How is immunotherapy used in the treatment of early-onset sepsis (EOS) in neonates of mothers with chorioamnionitis?

Updated: May 08, 2018
  • Author: Fayez M Bany-Mohammed, MD; Chief Editor: Ted Rosenkrantz, MD  more...
  • Print

Guidelines for immunotherapy in early-onset sepsis (EOS) are not well established. Treatments used include administration of granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor (GM-CSF) (eg, filgrastim, sargramostim), [226] and intravenous administration of immunoglobulin G (IgG), [225] particularly if a high-titer IgG antibody is specifically directed against the bacterial pathogen. Despite extensive research on neonatal immunotherapies, no agreement regarding their use has been reached. A future area of intensive research is maternal immunomodulation therapy for prevention of preterm birth, prematurity-related morbidity, and neonatal infections. [236] An example of such maternal immunomodulation would be the development of a maternal GBS vaccine to prevent invasive GBS disease in the newborn, an issue that is under intensive investigation. [237]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!